Argus Research Maintains Buy on Versigent, Raises Price Target to $54

Benzinga Newsdesk www.benzinga.com Positive 61.9%

Neg 0% Neu 0% Pos 61.9%

Argus Research analyst Bill Selesky maintains Versigent (NYSE:VGNT) with a Buy and raises the price target from $50 to $54.